+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06127407

Phase 3 Study of Oral Ivosidenib Versus Placebo in Adults With Locally Advanced or Metastatic Conventional Chondrosarcoma Having an IDH1 Mutation and Previous Systemic Treatments

Led by Servier Bio-Innovation LLC · Updated on 2026-10-28

156

Participants Needed

115

Research Sites

147 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of oral ivosidenib in adults with locally advanced or metastatic conventional chondrosarcoma that has an IDH1 gene mutation. This Phase 3, international, multicenter, double-blind study compares ivosidenib to a placebo in participants who have measurable disease that has progressed or recurred and who have received up to two prior systemic treatments. The trial focuses on progression-free survival as the primary outcome, especially in Grades 1 and 2 chondrosarcoma participants. Participants will be randomly assigned to receive either ivosidenib 500 mg tablets or matching placebo tablets taken orally once daily. Treatment continues until disease progression confirmed by a blinded independent central review, unacceptable side effects, pregnancy, death, withdrawal, loss to follow-up, or study end. Those on placebo who experience disease progression and meet criteria may cross over to receive ivosidenib. The estimated average treatment duration is about two years. During the study, participants will undergo regular imaging scans to assess tumor response and progression according to RECIST criteria. Researchers will monitor survival outcomes up to five years and evaluate safety through adverse event reporting. Quality of life questionnaires and blood tests to measure drug and biomarker levels will be collected. The total participation duration may extend up to five years, including treatment and follow-up assessments.

CONDITIONS

Brief Title

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens

Research Team

I

Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here